After 109% Rally, Moderna’s Pipeline Progress and 10% Revenue Goal

Biotech insiders see Moderna’s 109% stock surge as validation that mRNA platforms can transcend COVID—provided the company delivers on ambitious pipeline targets and avoids another CMV-like failure.

Moderna’s stock has roared back in 2026, surging 109% year-to-date as of mid‑July, prompting CNBC’s Jim Cramer to declare the biotech ‘finally investable again’ after a brutal post‑pandemic selloff that wiped more than 80% from its peak value. The dramatic rally has been fueled not by a single blockbuster approval but by a series of hard‑won operational improvements: aggressive cost‑cutting, a sharpened pipeline focus, and early signs that the mRNA platform can transcend its COVID‑19 origins. With the shares now easing from recent highs, investors are asking whether the pullback is a no‑brainer buying opportunity or a value trap masking unresolved risks.

“

Moderna’s stock has roared back in 2026, surging 109% year-to-date as of mid‑July, prompting CNBC’s Jim Cramer to declare the biotech ‘finally investable again’ after a brutal post‑pandemic selloff that wiped more than 80% from its peak value.

The narrative that drove Moderna to a peak market capitalization exceeding $100 billion in 2021 was entirely built on its coronavirus vaccine. At the time, revenues from the shot dwarfed everything else in the portfolio, and the stock price followed suit, rocketing more than 2,000% from the beginning of 2020 to August 2021. That dependency became a liability when vaccine demand normalized, and Moderna reported successive quarters of declining sales and widening losses. Compounding the downturn, the company’s first major non‑COVID product—an RSV vaccine—generated lackluster initial sales, while its once‑promising cytomegalovirus (CMV) candidate failed a pivotal late‑stage trial. Those setbacks, combined with a development pipeline that seemed permanently stuck in the shadow of the pandemic triumph, pushed the shares to depths where many institutional investors walked away.

What has changed in 2026 is management’s willingness to restructure the business. In its most recent quarterly update, the company reiterated a goal of as much as 10% revenue growth this year and disclosed a 26% year‑over‑year reduction in operating expenses. The cost discipline extends across both R&D and SG&A, redirecting resources toward the most promising clinical programs while pruning less advanced assets. For the first time since the pandemic windfall, Moderna is credibly demonstrating a path to profitability that does not depend on another global health emergency. The market has responded accordingly, with the stock not only recouping 2025 losses but also outperforming the broader biotech sector by a wide margin.

The Jim Cramer endorsement adds a layer of retail‑investor enthusiasm that can accelerate momentum. Cramer’s ‘investable again’ label serves as a sentiment signal, often attracting short‑term money that magnifies moves in both directions. While Cramer’s calls are no substitute for fundamental analysis, his ability to shape narrative means that increased attention will likely bring more scrutiny to Moderna’s upcoming catalysts: the ongoing RSV commercial rollout, data from combination vaccine programs, and the progress of early‑stage oncology and latent virus assets. A positive readout could provide the next leg higher; a disappointment could just as quickly reverse the gains.